Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

d for the full year 2007.

General and administrative expenses in the fourth quarter of 2007 decreased to $1.8 million from $3.0 million in the year ago period resulting mainly from cost controls and less outsourced services. General and administrative expenses for the full year 2007 decreased to $6.1 million from $7.7 million for the full year 2006. This decrease was principally a result of legal and consulting expenses capitalized upon the completion of the IPO in 2007 compared to costs related to the unsuccessful IPO attempt in 2006 that were expensed.

On December 31, 2007, ImaRx had $12.9 million in cash, cash equivalents and investments, excluding $0.4 million in restricted cash, compared to $4.3 million in cash, cash equivalents and investments on December 31, 2006. The increase in the cash balance was primarily related to the $9.0 million sale of Abbokinase, net of discounts and fees, to two primary wholesale distributors and the $12.4 million in net proceeds received from the common stock offering in connection with the Company's July 2007 IPO. Assuming the tentative agreement with Abbott regarding the remaining balance of the $15.0 million note is executed and a strategic financing alternative for SonoLysis is achieved, the Company believes it will have sufficient cash resources for at least the next 12 months.

Additionally, in connection with the filing of its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2008, Ernst & Young LLP, the Company's independent registered public accounting firm, noted that the Company has recurring losses, which has resulted in a significant accumulated deficit at December 31, 2007. In addition, the Company has a significant note payable balance due on March 31, 2008. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern.

Conference Call and Webcast Information

Management will host a conferen
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... market is one of the most attractive in the ... plus a growing economy and increasing government investment in ... The Russian market is set to grow at twice ... estimates around 10-15% annually reaching an approximate market value ... Cross Green Cross provides total healthcare solutions ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 The ... of smartphones have fuelled social media growth, with ... currently engaged in social networking. Insurance companies are ... communicate with clients and promote a diversity of ... over are increasingly exploiting social networking services as ...
(Date:3/25/2015)... and REYKJAVIK, Iceland , March 25, 2015 ... the genome to create better medicine, today congratulated the scientists ... of whole-genome data yet undertaken. The studies ... – are built around the most comprehensive population-wide tally ... deCODE scientists led by Kari Stefansson , deCODE,s founder ...
(Date:3/25/2015)... 2015 Having added two International locations ... of 2014, ITRA Global proudly announced recently the organization’s ... Representative Alliance, based in the United States, is one ... occupiers of commercial real estate. , Saltwood International ... Poland that exclusively advises occupiers of office space, ensuring ...
Breaking Biology Technology:Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2International Organization Expands its Global Reach to Warsaw, Poland 2
... a,biotechnology company translating the complexity of human biology to,develop ... manager of its Scientific Programs, was selected by Mass ... "We are proud to have a young, successful individual ... O. Elliston, president and CEO at,Genstruct. "She has been ...
... of Venous Thromboembolism -, LEXINGTON, Mass., Oct. ... US Food and Drug Administration (FDA) has,granted 510(k) ... D-Dimer HS,to exclude venous thromboembolism (VTE) in outpatients ... (PE), when used in conjunction,with a clinical pretest ...
... Oct. 9 A homegrown New Jersey company ... pedigree of pharmaceuticals everywhere. Secure Symbology, (http://www.securesymbology.com ), ... as an,Honored Finalist as Emerging Business of the ... for its vision to wipe out counterfeit drugs,worldwide. ...
Cached Biology Technology:Genstruct's Andrea Matthews Selected for Mass High Tech's 'People to Watch Under 30' 2Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use for HemosIL(R) D-Dimer HS Assay 2Secure Symbology: Making New Jersey Proud While Saving Lives 2
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
(Date:3/12/2015)... , March 12, 2015 ... a standardized identity and access management (IAM) solution ... implementation schedule. With Beta System,s new IAM package, ... best practices gleaned from multiple IAM implementations across ... the software as well as any necessary services ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... Virginia Key, Fla. -- Ronald Hoenig and Aaron ... Miami (UM) Rosenstiel School of Marine UM Rosenstiel ... 6th Rothschild Entrepreneurship Competitionand Atmospheric Science, won first ... years 6th Annual Leigh Rothschild Entrepreneurship Competition. ...
... at San Antonio will bring together energy leaders, industry ... hosts the inaugural UTSA North American Energy Summit (NAES) ... UTSA Downtown Campus. The summit will feature experts with ... addressing the energy needs for future generations. ...
... the latest American Chemical Society (ACS) News Service Weekly PressPac ... Engineering News.,Please credit the individual journal or the American Chemical ... IS FOR IMMEDIATE USE EXCEPT ARTICLE #5, which is embargoed ... ARTICLE #1 FOR IMMEDIATE RELEASE Study calls for ...
Cached Biology News:Aquaculture concept leaves judges 'goggle eyed' 2UTSA hosts North American Energy Summit May 1-2 2American Chemical Society's Weekly PressPac -- April 23, 2008 2American Chemical Society's Weekly PressPac -- April 23, 2008 3American Chemical Society's Weekly PressPac -- April 23, 2008 4American Chemical Society's Weekly PressPac -- April 23, 2008 5American Chemical Society's Weekly PressPac -- April 23, 2008 6American Chemical Society's Weekly PressPac -- April 23, 2008 7American Chemical Society's Weekly PressPac -- April 23, 2008 8
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
Rat Hepatocytes (RH) (>3,000,000 cells)...
... the detection of very small amounts of ... with improved resolution (20,000) and mass accuracy ... in protein identification. The AXIMA-CFRplus also includes ... target handling and the ability to analyse ...
...
Biology Products: